Literature DB >> 22213030

T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.

Matthew D Morse1, Douglas G McNeel.   

Abstract

BACKGROUND: T cells infiltrate the prostates of prostate cancer patients undergoing neoadjuvant androgen deprivation. These prostate-infiltrating T cells have an oligoclonal phenotype, suggesting the development of an antigen-specific T-cell response. We hypothesized that androgen deprivation might elicit a prostate tissue-specific T-cell response that could potentially be combined with other immune-active therapies, and consequently sought to investigate the nature and timing of this T-cell response following castration.
METHODS: We investigated the phenotype and cytokine expression of T cells at various time points in the prostates of Lewis rats following surgical castration, and used adoptive transfer of prostate-infiltrating lymphocytes (PILs) to determine whether the infiltration by T cells was mediated by effects of castration on the prostate or lymphocytes.
RESULTS: Prostate T-cell infiltration shortly after castration was T(H) 1 biased up to approximately 30 days, followed by a predominance of T(H) 17-type cells, which persisted until at least 90 days post castration. PILs from sham-treated or castrate rats localized to the prostates of castrate animals.
CONCLUSIONS: These observations suggest castration elicits a time-dependent prostate-specific T-cell infiltration, and this infiltration is likely mediated by effects of castration on prostate tissue rather than T-cells. These findings have implications for the timing of immunotherapies combined with androgen deprivation as treatments for prostate cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22213030      PMCID: PMC3673717          DOI: 10.1002/pros.22476

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

Review 1.  Update on prostate cancer vaccines.

Authors:  Charles G Drake
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response.

Authors:  M Dalal; S Kim; R R Voskuhl
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

3.  CCL25 increases thymopoiesis after androgen withdrawal.

Authors:  Kirsten M Williams; Philip J Lucas; Catherine V Bare; Jiun Wang; Yu-Waye Chu; Ezekiel Tayler; Veena Kapoor; Ronald E Gress
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

4.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Authors:  Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

5.  Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.

Authors:  Carlo Sorrentino; Piero Musiani; Paolo Pompa; Giuseppe Cipollone; Emma Di Carlo
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

6.  Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids.

Authors: 
Journal:  Trends Endocrinol Metab       Date:  1999-03       Impact factor: 12.015

7.  The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis.

Authors:  M J Naslund; J D Strandberg; D S Coffey
Journal:  J Urol       Date:  1988-11       Impact factor: 7.450

8.  Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.

Authors:  Evelyna Derhovanessian; Victoria Adams; Karin Hähnel; Andrea Groeger; Hardev Pandha; Stephen Ward; Graham Pawelec
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

Review 9.  FLIP-ping out: death receptor signaling in the prostate.

Authors:  Kent L Nastiuk; John J Krolewski
Journal:  Cancer Biol Ther       Date:  2008-08-01       Impact factor: 4.742

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  8 in total

Review 1.  Androgen deprivation and immunotherapy for the treatment of prostate cancer.

Authors:  Melissa Gamat; Douglas G McNeel
Journal:  Endocr Relat Cancer       Date:  2017-08-16       Impact factor: 5.678

Review 2.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

3.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Authors:  Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel
Journal:  Clin Genitourin Cancer       Date:  2013-07-05       Impact factor: 2.872

4.  Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Authors:  C Sanchez; R Chan; P Bajgain; S Rambally; G Palapattu; M Mims; C M Rooney; A M Leen; M K Brenner; J F Vera
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-01-08       Impact factor: 5.554

5.  Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Authors:  Brian M Olson; Melissa Gamat; Joseph Seliski; Thomas Sawicki; Justin Jeffery; Leigh Ellis; Charles G Drake; Jamey Weichert; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2017-10-19       Impact factor: 11.151

6.  Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.

Authors:  Qiuyang Zhang; Sen Liu; Qingsong Zhang; Zhenggang Xiong; Alun R Wang; Leann Myers; Jonathan Melamed; Wendell W Tang; Zongbing You
Journal:  Prostate       Date:  2014-04-01       Impact factor: 4.104

Review 7.  Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.

Authors:  Jennifer L Kalina; David S Neilson; Alexandra P Comber; Jennifer M Rauw; Abraham S Alexander; Joanna Vergidis; Julian J Lum
Journal:  Cancers (Basel)       Date:  2017-01-27       Impact factor: 6.639

Review 8.  Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Authors:  Melissa Gamat-Huber; Donghwan Jeon; Laura E Johnson; Jena E Moseman; Anusha Muralidhar; Hemanth K Potluri; Ichwaku Rastogi; Ellen Wargowski; Christopher D Zahm; Douglas G McNeel
Journal:  Cancers (Basel)       Date:  2020-09-30       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.